A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Clinical Cancer Genetics Bookmark and Share

Clinical Cancer Genetics

 
 
 Mission Statement:
 The City of Hope Division of
 Clinical Cancer Genetics is
 committed to being a national
 leader in the advancement
 of cancer genetics, screening
 and prevention, through
 innovative patient care,
 research and education.
 
 
In light of a growing body of research confirming that many common cancers, including breast, ovarian, and colorectal cancer, are hereditary, the Division of Clinical Cancer Genetics (CCG) Cancer Screening & Prevention Program helps people understand their personal cancer risk profiles, offering a comprehensive cancer risk assessment that takes into account family history and genetics, along with environmental and lifestyle factors. With this information, people can take proactive steps to “outsmart cancer.”
 
 
 
 
The division’s Cancer Genetics Education Program (CGEP) offers courses and professional development tools designed to further health care professionals’ understanding of cancer genetics.
 
 

Major initiatives include:

The Intensive Course (IC) promotes community-based, practitioner-level competence in the selection, application and interpretation of genetic testing in order to provide these critical services in underserved areas.
 
 
 
The Clinical Cancer Genetics Community of Practice (CCGCoP) is a network of clinicians who have graduated from the IC and/or the Cancer Genetics Career Development Program (CGCDP), along with members of the CCGCRN. Those who are part of this unique community have access to collaborators and professional support from other community members, and to enhanced continuing professional development activities offered by CCG.
 
 
 
In the Cancer Genetics Career Development Program, outstanding post-graduate research scientists receive training with a focus on cutting edge genetic and genomic technology. Graduates of this program continue their work in cancer genetics with the goal of reducing the burden of cancer among those at highest risk.
 
 
 
Clinical cancer genetics research at City of Hope investigates multiple approaches that utilize the latest findings in cancer genetics in order to improve the prevention, treatment, and support of those with hereditary cancers.
 
 
 
Major initiatives include:
 
The CCG molecular genetics research laboratory uses a multitude of research tests such as MLPA, long range PCR and next generation sequencing as well as a variety of state of the art equipment to prescreen high risk patients for mutations in cancer predisposition genes such as BRCA1, BRCA2 and RAD51. Specific equipment available in the laboratory include:  -Sequenom MassArray Analyzer (MALDI-TOF Mass spectrometry) -Sequenom MassArray Robotic Nanodispenser -Ion Torrent Personal Genome Machine -Ion One Touch -Nanodrop 2000c spectrophotometer -Qubit 2.0 Fluorometer -ABI 3130xl Genetic Analyzer -Veriti 96 well thermocyclers -Gene Amp 9700 PCR systems
 
 
 
 
An essential but often unmet aspect of providing quality care to persons affected by cancer or those at hereditary cancer risk is addressing their psychosocial needs. As such, understanding and minimizing the negative impact of hereditary cancer risk on persons' lives is the focus of the CCG Clinical and Behavioral Research program. The program studies health-related behaviors, quality of life (including emotional, psychological and basic daily living needs), and ethical, legal, and social issues, by going directly to the source--our patients and their family members.
 
 
 
 
An integral component of the research program is the Cancer Genetics Community Research Network (CCGCRN), a prospective research registry protocol initiated at City of Hope as a biospecimen repository with associated personal and family medical history, and psychosocial and clinical follow-up data collection. Collaborating community-based oncogenetic practice sites across the U.S. and Latin America are recruiting thousands of genetic cancer risk assessment patients annually.
 
 
 
 
 
In addition, CGEP staff participate in educational outreach to medical groups, hospital medical staffs and other community health care professionals. The program is supported in part by the National Cancer Institute and the California Research Program.
 

Clinical Cancer Genetics

Clinical Cancer Genetics

 
 
 Mission Statement:
 The City of Hope Division of
 Clinical Cancer Genetics is
 committed to being a national
 leader in the advancement
 of cancer genetics, screening
 and prevention, through
 innovative patient care,
 research and education.
 
 
In light of a growing body of research confirming that many common cancers, including breast, ovarian, and colorectal cancer, are hereditary, the Division of Clinical Cancer Genetics (CCG) Cancer Screening & Prevention Program helps people understand their personal cancer risk profiles, offering a comprehensive cancer risk assessment that takes into account family history and genetics, along with environmental and lifestyle factors. With this information, people can take proactive steps to “outsmart cancer.”
 
 
 
 
The division’s Cancer Genetics Education Program (CGEP) offers courses and professional development tools designed to further health care professionals’ understanding of cancer genetics.
 
 

Major initiatives include:

The Intensive Course (IC) promotes community-based, practitioner-level competence in the selection, application and interpretation of genetic testing in order to provide these critical services in underserved areas.
 
 
 
The Clinical Cancer Genetics Community of Practice (CCGCoP) is a network of clinicians who have graduated from the IC and/or the Cancer Genetics Career Development Program (CGCDP), along with members of the CCGCRN. Those who are part of this unique community have access to collaborators and professional support from other community members, and to enhanced continuing professional development activities offered by CCG.
 
 
 
In the Cancer Genetics Career Development Program, outstanding post-graduate research scientists receive training with a focus on cutting edge genetic and genomic technology. Graduates of this program continue their work in cancer genetics with the goal of reducing the burden of cancer among those at highest risk.
 
 
 
Clinical cancer genetics research at City of Hope investigates multiple approaches that utilize the latest findings in cancer genetics in order to improve the prevention, treatment, and support of those with hereditary cancers.
 
 
 
Major initiatives include:
 
The CCG molecular genetics research laboratory uses a multitude of research tests such as MLPA, long range PCR and next generation sequencing as well as a variety of state of the art equipment to prescreen high risk patients for mutations in cancer predisposition genes such as BRCA1, BRCA2 and RAD51. Specific equipment available in the laboratory include:  -Sequenom MassArray Analyzer (MALDI-TOF Mass spectrometry) -Sequenom MassArray Robotic Nanodispenser -Ion Torrent Personal Genome Machine -Ion One Touch -Nanodrop 2000c spectrophotometer -Qubit 2.0 Fluorometer -ABI 3130xl Genetic Analyzer -Veriti 96 well thermocyclers -Gene Amp 9700 PCR systems
 
 
 
 
An essential but often unmet aspect of providing quality care to persons affected by cancer or those at hereditary cancer risk is addressing their psychosocial needs. As such, understanding and minimizing the negative impact of hereditary cancer risk on persons' lives is the focus of the CCG Clinical and Behavioral Research program. The program studies health-related behaviors, quality of life (including emotional, psychological and basic daily living needs), and ethical, legal, and social issues, by going directly to the source--our patients and their family members.
 
 
 
 
An integral component of the research program is the Cancer Genetics Community Research Network (CCGCRN), a prospective research registry protocol initiated at City of Hope as a biospecimen repository with associated personal and family medical history, and psychosocial and clinical follow-up data collection. Collaborating community-based oncogenetic practice sites across the U.S. and Latin America are recruiting thousands of genetic cancer risk assessment patients annually.
 
 
 
 
 
In addition, CGEP staff participate in educational outreach to medical groups, hospital medical staffs and other community health care professionals. The program is supported in part by the National Cancer Institute and the California Research Program.
 
Clinical Cancer Genetics
The City of Hope Division of Clinical Cancer Genetics is committed to being a national leader in the advancement of cancer genetics, screening and prevention, through innovative patient care, research and education.

Contact Us
  • 800-826-HOPE (4673)
  • For more information about the Cancer Screening & Prevention Program, call 626-256-8662, ext. 2.
Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
City of Hope Breakthroughs
Get the latest in City of Hope's research, treatment and news you can use on our blog, Breakthroughs.
 
 


NEWS & UPDATES
  • “World-class expertise,” “leading-edge research” and “compassionate patient care” are not just words at City of Hope; they’re a way of life. No one knows this more than City of Hope’s patients. On New Year’s Day, six of those patients and their loved ones – ...
  • The protein HER2 is most commonly associated with breast cancer, but it also plays a role in several other cancers — including  esophageal cancer. Using this knowledge and the drug trastuzumab (Herceptin), which targets HER2, City of Hope researchers are conducting clinical trials with the hope of improving sur...
  • A new therapy is offering hope to patients with a certain form of acute lymphoblastic leukemia (ALL). The drug recently received approval by the U.S. Food and Drug Administration, thanks in part to studies conducted by Anthony Stein, M.D., at City of Hope. The drug Blincyto, also known by its generic name of bl...
  • Too often, the symptoms of esophageal cancer are mistaken for those of more benign conditions. That’s an easy mistake to make because many people do experience such symptoms every now and then, including trouble swallowing, hoarseness, coughing, frequent vomiting or hiccupping, even the more alarming ches...
  • Cancer cells are voracious eaters. Like a swarm of locusts, they devour every edible tidbit they can find. But unlike locusts, when the food is gone, cancer cells can’t just move on to the next horn o’ plenty. They have to survive until more food shows up — and they do. Mei Kong, Ph.D., assistant […]
  • On Jan. 1, 2015, six City of Hope patients who have journeyed through cancer will welcome the new year with their loved ones atop City of Hope’s Tournament of Roses Parade float. The theme of the float is “Made Possible by HOPE.” The theme of the parade is “Inspiring Stories.” Repr...
  • When 25-year-old Angelina Mattos was diagnosed with Stage 4 oral cancer earlier this year, she learned that her only hope of survival was through the removal of her tongue, a surgery that leaves people without the ability to talk or eat normally, sometimes permanently ending their ability to speak. After hearin...
  • Two years ago, Joselyn Miller and her family sat together as stem cells from her brother’s bone marrow were infused into her – a precious gift of life that the family is excited to have the chance to pass to another patient in need. Today, the stem cell recipient is healthy. Her 23-year-old son Rex, who […...
  • Even as the overall rate of oral cancers in the United States steadily declines, the rate of tongue cancer is increasing — especially among white females ages 18 to 44. An oral cancer diagnosis, although rare, is serious. Only half of the people diagnosed with oral cancer are still alive after five years, accor...
  • Sometimes cancer found in the lungs is not lung cancer at all. It can be another type of cancer that originated elsewhere in the body and spread, or metastasized, to the lungs through the bloodstream or lymphatic system. These tumors are called lung metastases, or metastatic cancer to the lungs, and are not the...
  • When it comes to research into the treatment of hematologic cancers, City of Hope scientists stand out. One study that  they presented this week at the annual meeting of the American Society of Hematology suggests a new standard of care for HIV-associated lymphoma, another offers promise for the treatment of re...
  • Patients with HIV-associated lymphoma may soon have increased access to the current standard of care for some non-HIV infected patients – autologous stem cell transplants. Impressive new data, presented Monday at the annual meeting of the American Society of Hematology (ASH) in San Francisco, indicate that HIV-...
  • On Jan. 1, 2015, six City of Hope patients who have journeyed through cancer will welcome the new year with their loved ones atop City of Hope’s Tournament of Roses Parade float. The theme of the float is “Made Possible by HOPE.” The theme of the Rose Parade is “Inspiring Stories.”...
  • The holidays can create an overwhelming urge to give to people in need — especially to sick children and families spending the holidays in a hospital room. That’s a good thing. Holiday donations of toys and gifts can bolster the spirits, and improve the lives, of people affected by illness, and hospitals ...
  • On Jan. 1, 2015, six City of Hope patients who have journeyed through cancer will welcome the new year with their loved ones atop City of Hope’s Tournament of Roses Parade float. The theme of the float is “Made Possible by HOPE.” The theme of the parade is “Inspiring Stories.” Here...